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Purpose: The cytokine transforming growth factor-β (TGF-β), and the ED-A splice variant of the extracellular matrix
protein fibronectin modulate wound healing and scar formation. To further elucidate their possible role in filtering bleb
scarring after glaucoma surgery in human eyes in vivo, we studied the cell type specific localization of TGF-β receptors
and the presence of ED-A fibronectin in sections of normal conjunctiva and scarred filtering blebs.
Methods: Cryosections of normal conjunctiva (four patients) and scarred filtering blebs (seven patients) were studied by
double-label immunofluorescence. Antibodies against PECAM-1 and prolyl-4-hydroxylase allowed for specification of
vascular endothelial cells and activated fibroblasts, respectively. TGF-β receptor type II (TGF-β-RII), α-smooth muscle
actin, O-linked sialoglycoprotein, fibronectin and the ED-A fibronectin splice-variant were also detected using specific
antibodies. Labeled sections were viewed with a confocal laser scanning microscope.
Results: Vascular endothelial cells expressed TGF-β-RII in both normal and scarred tissue. TGF-β-RII was sparsely
detected in the fibroblasts of normal conjunctiva while it was strongly expressed in most fibroblasts of the scarred filtering
blebs. Similarly, ED-A fibronectin was not detected in the extracellular matrix of normal conjunctiva but abundantly
present in scarred filtering blebs.
Conclusions: Filtering bleb scarring is associated with an abundant expression of TGF-β receptors in activated fibroblasts
and the deposition of the fibrogenic ED-A fibronectin splice-variant. These data support the concept of targeting TGF-β
signaling to prevent scar formation after filtering glaucoma surgery.
Scar  formation  is  the  most  frequent  cause  of  failure
following  glaucoma  filtering  surgery,  but  the
pathophysiological mechanisms of filtering bleb scarring are
not fully elucidated. The cytokine transforming growth factor-
β (TGF-β), is pivotal in wound healing and scar formation in
general [1,2]. All three TGF-β isoforms have been identified
in the eye [3,4] with TGF-β-2 being the predominant isoform
associated with ocular scarring diseases such as proliferative
vitreoretinopathy and cataract formation [5,6]. In a mouse
model  of  conjunctival  scarring,  TGF-β-2  was  strongly
expressed in the stroma of the wounded area [7] and a TGF-
β-2-specific  neutralizing  antibody  prevented  conjunctival
scarring  after  glaucoma  surgery  in  a  rabbit  model  [8].
However, a recent phase III clinical trial failed to demonstrate
a  significant  effect  of  TGF-β-2-specific  antibodies  in  the
prevention  of  filtering  bleb  scarring  [9]  and  raised  some
reservations concerning the targeting of TGF-β.
In the early phases of wound healing, TGF-β is secreted
by inflammatory cells [10] and acts as a chemoattractant. In
the  long-term,  TGF-β  promotes  the  transdifferentiation  of
fibroblasts to highly contractile myofibroblasts, which deposit
extracellular matrix proteins and serve as the main agents of
scarring  if  present  persistently.  TGF-β  binds  to  a
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heterodimeric receptor complex, consisting of two serine-
threonine kinase receptors designated TGF-β type I and II
receptor, and leads to the activation of several intracellular
signaling  pathways.  The  tissue  distribution  of  TGF-β
receptor-bearing  cells  in  normal  conjunctiva  and  scarred
filtering blebs is currently unclear.
Furthermore, scarring is associated with alterations in the
extracellular  matrix  composition.  TGF-β  induces  the
expression of the ED-A fibronectin splice variant [11] as a
precondition  for  TGF-β-mediated  myofibroblast
transdifferentiation.  Studies  in  vitro  revealed  that  TGF-β-
induced myofibroblast transdifferentiation was averted by the
blocking of ED-A fibronectin with specific antibodies [11].
The role of ED-A fibronectin in filtering bleb scarring has not
been addressed.
To gain further insight into the possible role of TGF-β in
filtering bleb scarring in human eyes in vivo, we studied the
cell type-specific distribution of TGF-β-RII and the presence
of  ED-A  fibronectin  in  normal  conjunctiva  and  scarred
filtering blebs.
METHODS
Tissue  samples:  Conjunctival  specimens  were  obtained
during  standard  intraocular  surgery  after  comprehensive
information and written consent of the selected patients. The
tenets of the Declaration of Helsinki were followed, and an
institutional  ethics  committee  approval  had  been  granted.
Native  conjunctival  tissue  was  gained  from  four  patients
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136undergoing strabismus surgery while hypertrophic scar tissue
was obtained from seven patients undergoing filtering bleb
revision surgery after multiple preceding operations (Table 1).
All specimens were embedded in Tissue Tek cryopreservant
and snap frozen in liquid nitrogen.
Tissue  processing  and  immunofluorescent  staining:  The
following antibodies were used: rabbit anti-TGF-β-RII (L-21,
Santa Cruz Biotechnology, Santa Cruz, CA), and monoclonal
mouse anti-PECAM-1 (DAKO, Glostrup, Denmark) to detect
vascular endothelial cells; anti-α-SMA, anti-FN, anti-ED-A-
FN  (Sigma,  St.Louis,  MO),  and  anti-O-linked
sialoglycoprotein (D2–40, Signet Laboratories, Dedham) to
detect  lymphatic  endothelium;  and  mouse  anti-prolyl-4-
hydroxylase (DAKO) directed against an enzyme involved in
posttranslational  collagen  modification  to  detect  activated
fibroblasts.  Secondary  antibodies  were  labeled  with
Alexa-488  or  Alexa-568  (Molecular  Probes,  Leiden,  The
Netherlands).  Cryostat  sections  of  6  µm  thickness  were
prepared, air dried, fixed in pure acetone for 20 min at −20 °C,
and blocked for 1 h in TRIS buffered saline (TBS, pH 7.6),
containing 4% normal goat serum (NGS, Dianova, Hamburg,
Germany). Antibodies were diluted in TBS, containing 1%
NGS plus 0.1% Triton X-100. The primary antibodies were
incubated  overnight  at  4  °C  in  a  humidified  chamber.
Secondary antibodies were applied sequentially for 1 h at
room temperature. Following each incubation, the specimens
were  washed  three  times  in  TBS  and  finally  mounted  in
Vectashield (Vector, Burlingame, CA). The stained slides
were viewed with a laser scanning confocal microscope (TCS
SP-2, Leica, Bensheim, Germany).
RESULTS
Increased cell density in scarred filtering blebs: In normal
conjunctiva,  the  subepithelial  stroma  contained  sparse
fibroblasts and occasional small vascular structures (Figure
1A, arrows). Specimens of scarred filtering blebs showed a
high density of spindle-shaped cells, presumably fibroblasts,
several vascular structures, and areas of inflammatory cell
infiltrates (Figure 1B). Only one scar specimen and all normal
specimens contained an epithelial layer. To avoid leakage and
allow for proper wound closure after revision surgery, care
was taken to spare the conjunctival epithelial layer, which
explains the absence of epithelium in most scar specimens.
TGF-β  receptor  II  expression  in  native  conjunctiva  and
scarred filtering blebs: To assess TGF-β receptor expression
and identify TGF-β-responsive cell types, immunofluorescent
double stains were performed. Vascular endothelial cells were
Figure 1. Increased cell density in scarred filtering blebs. Normal
conjunctiva (A) shows loose subepithelial connective tissue with
sparse fibroblasts and occasional vascular structures (arrows). In
contrast, scarred filtering blebs (B) are characterized by compacted
connective tissue with abundant spindle-shaped cells and various
vascular structures. H&E stains.
TABLE 1. PATIENT CHARACTERISTICS
Age [yrs] Sex Diagnosis Previous Surgery [#of
proc.]
Time after
previous surgery
[mo]
History of topical
medication
14 f Strabismus 0 - -
29 f Strabismus 0 - -
6 m Strabismus 0 - -
28 m Strabismus 0 - -
53 m Glaucoma / POAG 4 2 + / multiple Allergies
8 m 2° Glaucoma after injury 5 1 + Hx of 6 years
62 m 2° Glaucoma after injury 5 1 + / Hx of 16yrs
79 f Glaucoma / PEX 1 2 + / Hx of 3yrs
37 f Glaucoma / juvenile 4 8 + / Hx of 14yrs
53 m Glaucoma / uveitic 2 2 + / Hx of 5yrs
Survey of patient characteristics including age, sex, reason for surgery (strabismus surgery or glaucoma surgery), type of
glaucoma, number and time after previous surgery, history of topical medication. All patients undergoing revision glaucoma
surgery received topical mitomycin C treatment. Abbreviations: POAG: primary open angel glaucoma; PEX: pseudoexfoliation
glaucoma.
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137stained  with  an  antibody  recognizing  PECAM-1,  and
activated fibroblasts were detected using an antibody against
the enzyme prolyl-4-hydroxylase. TGF-β-RII expression was
strong  in  epithelial  cells  (Figure  2A)  and  in  vascular
endothelial  cells  (Figure  2A,B,C).  Activated,  prolyl-4-
hydroxylase-positive  fibroblasts  were  absent  in  normal
conjunctiva, and a faint staining for TGF-β-RII was rarely
seen in non-vascular areas of the normal conjunctival stroma
(Figure 2A and Figure 3A).
Specimens of scarred filtering blebs were rich in vascular
structures as detected by PECAM-1 staining (Figure 2B,C).
PECAM-1  positive  cells  stained  for  TGF-β-RII  (Figure
2B,C),  but  non-vascular  spindle-shaped  cells  were  also
expressing this receptor (Figure 2C, arrows). The latter appear
to be activated fibroblasts as detected by an anti-prolyl-4-
hydroxylase  antibody  (Figure  3B,C).  These  cells  were
abundant  in  scarred  filtering  blebs,  and  most  of  them
expressed  TGF-β-RII  (Figure  3B,C,  arrows).  In  scarred
filtering  blebs,  fibroblasts  also  expressed  α-SMA  (Figure
4B,C),  which  was  detected  in  perivascular  cells  as  well.
Lymphatic endothelium was not detected (Figure 4E,F).
No  staining  was  observed  when  the  anti-TGF-β-RII
antibody was preadsorbed to a specific control peptide, or
when non-immune rabbit IgG was used as a primary antibody
as well as when primary antibodies were omitted (data not
shown).
Fibronectin and ED-A fibronectin in native conjunctiva and
scarred  filtering  blebs:  To  study  fibronectin  extracellular
matrix  composition  in  conjunctival  tissue,  we  performed
double stains using antibodies against total fibronectin and the
ED-A  fibronectin  splice  variant.  Fibronectin  was  found
throughout  the  subepithelial  stroma  in  both  the  normal
conjunctiva  and  scarred  filtering  blebs  (Figure  5A,B).  In
normal conjunctiva, expression of the ED-A fibronectin splice
variant was restricted to perivascular areas and basal epithelial
cells (Figure 5A). In contrast, ED-A fibronectin was present
throughout the stroma of scarred filtering blebs (Figure 5B).
DISCUSSION
Scar formation remains a serious problem following filtering
glaucoma  surgery.  The  cytokine  TGF-β,  promotes  the
transdifferentiation  of  human  tenon  fibroblasts  to
Figure 2. Colocalization of TGF-β-RII
and PECAM-1. Native conjunctiva (A)
and  scarred  filtering  bleb  specimens
(B, C) were double-stained for TGF-β-
RII (green) and the vascular endothelial
cell  marker,  PECAM-1  (red).  C  is  a
close-up of a section of B as indicated
by the frame. Arrows point to elongated
TGF-β-RII  positive  cells  devoid  of
PECAM-1 signal, which are most likely
fibroblasts. Scale bar represents 50 µm
(A, B) and 10 µm (C).
Figure 3. Colocalization of TGF-β-RII
and  the  fibroblast  marker  prolyl-4-
hydroxylase.  Native  conjunctiva  (A)
and  scarred  filtering  bleb  specimens
(B, C) were double-stained for TGF-β-
RII  (green)  and  prolyl-4-hydroxylase
(red). C is a close-up of a portion of B
as indicated by the frame. Arrows point
to  a  TGF-β-RII  positive  fibroblast,
which are positive for both TGF-β-RII
and  prolyl-4-hydroxylase.  Scale  bar
represents 50 µm (A,B) and 10 µm (C).
Molecular Vision 2008; 14:136-141 <http://www.molvis.org/molvis/v14/a17> © 2008 Molecular Vision
138myofibroblasts in vitro and has been detected in conjunctival
epithelium  and  subepithelial  extracellular  matrix  after
glaucoma surgery [12,13]. However, data on the localization
of the respective TGF-β receptors in conjunctival tissue have
been lacking. A recent phase III clinical trial, which failed to
show an advantage of a topical administered antibody against
TGF-β-2 over placebo has raised some reservations regarding
the effectiveness of TGF-β-antagonizing strategies to prevent
filtering bleb scarring. To further address the relevance of
TGF-β in human filtering bleb scarring in vivo, we assessed
the  cell  type-specific  localization  of  TGF-β  receptors  in
normal conjunctiva and scarred filtering blebs. Furthermore,
we  examined  the  distribution  of  ED-A  fibronectin  as  an
indicator for TGF-β-induced extracellular matrix alterations.
TGF-β receptors were detected in conjunctival epithelial
cells and in vascular endothelial cells of both the normal
conjunctiva and scarred filtering blebs. This is consistent with
studies of cutaneous squamous epithelium [14] where TGF-
β exerts homeostatic and antiproliferative effects [15]. The
significance of TGF-β in angiogenesis is also well established
although the exact effects of TGF-β on vascular endothelial
cells have not fully unraveled. Transgenic mice deficient in
TGF-β-1,  TGF-β  receptor  1  (ALK1),  TGF-β  receptor  2
Figure 4. Localization of α-smooth muscle actin (SMA) and the
absence of lymphatic endothelium in scarred filtering bleb tissue.
Serial sections were double labeled for TGF-β-RII (A, D, and G;
green) and α-SMA (B, C), O-linked sialoglycoprotein (E, F), and
PECAM-1 (H, I, red). α-SMA is colocalized to TGF-β-RII in stromal
fibroblasts  and  perivascular  cells  (A,B,C).  Vascular  structures
expressing TGF-β-RII(H) were negative for markers of lymphatic
endothelium (E).Some collagen fiber autofluorescence is present in
the red channel (B, E, H), Scale bar represents 50 µm.
(ALK4), or the accessory TGF-β-binding protein endoglin,
suffer  from  defects  in  angiogenesis  and  vascular
malformations  (reviewed  in  [16,17]).  An  increase  in
vascularity is an important clinical sign of impending filtering
bleb failure [18].
Most importantly, we provide evidence for a substantially
different  distribution  of  TGF-β  receptors  and  ED-A
fibronectin in the connective tissue of the normal conjunctiva
and  scarred  filtering  blebs.  As  detected  by
immunofluorescence, TGF-β receptors were virtually absent
in fibroblasts of normal conjunctiva while they were abundant
and  strongly  expressed  in  activated  fibroblasts  of  scarred
filtering blebs. Similarly, ED-A fibronectin was confined to
perivascular  areas  in  normal  conjunctiva  but  abundantly
present in all the scarred filtering blebs. In light of previous
studies by other investigators, these data are consistent with
TGF-β-induced alterations and indicate a state of enhanced
TGF-β responsiveness in scarred filtering blebs. A strong
TGF-β receptor expression can result from stimulation by
TGF-β [19,20] and has been demonstrated in subcutaneous
fibroblasts of granulation tissue and hypertrophic cutaneous
scars [14] as well as in an animal model of excisional wound
repair  [21].  Furthermore,  pronounced  TGF-β  receptor
expression results in enhanced TGF-β responses [22]. The
sparse  staining  for  TGF-β-RII  in  fibroblasts  of  normal
conjunctiva does not exclude TGF-β receptor expression but
rather indicates a low expression level close to the limit of
immunofluorescence  detection.  Human  tenon  fibroblasts,
derived from normal conjunctiva, respond to TGF-β in vitro
Figure 5. Expression of fibronectin and the ED-A fibronectin splice
variant. Fibronectin is abundant in normal conjunctiva (A) and in
scarred filtering blebs (B). In contrast, expression of the fibrogenic
ED-A fibronectin splice variant is restricted to perivascular areas in
normal conjunctiva (A), but expands throughout the tissue in scarred
filtering  blebs  (B).  Specimens  were  double-stained  for  total
fibronectin (green) and the fibronectin isoform, ED-A (red). Scale
bar represents 50 µm.
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139[23], and TGF-β, released during initial wound healing, may
well induce increased TGF-β receptor expression and auto-
induction  of  the  cytokine  TGF-β  [24],  in  conjunctival
fibroblasts.  Our  observation  of  strong  TGF-β  receptor
expression in subconjunctival fibroblasts of scarred filtering
blebs  may  thus  indicate  an  activated  deregulated  state  of
fibroblasts  with  increased  responsiveness  to  TGF-β.
Moreover, the increased expression of prolyl-4-hydroxlase,
an  enzyme  essential  in  collagen  processing,  suggests  the
activation of most fibroblasts in the scarred filtering blebs.
The recent observation that four subconjunctival injections of
a  monoclonal  anti-TGF-β2  antibody  had  no  effect  on
postoperative scarring in a phase III clinical trial [9] does not
rule out a role of TGF-β in the scarring process. Our current
data and previous studies suggest that the application regimen
used in the trial and the concept to distinctly target the TGF-
β2 isoform may deserve some reconsideration.
The  role  of  cell-matrix  interactions  in  shaping  the
response of tissue cells to extracellular stimuli is increasingly
acknowledged [25]. Fibronectin is a central component of the
extracellular  matrix  and  serves  both  as  a  structural  and
regulatory  element.  TGF-β  induces  expression  of  the
fibronectin  splice  variant,  ED-A,  which  is  essential  for
subsequent  TGF-β-induced  myofibroblast
transdifferentiation  [11].  In  line  with  these  data,  mice
deficient for the ED-A fibronectin isoform show impaired
wound  healing  [26].  On  the  other  hand,  persistence  of
activated  fibroblasts  and  ED-A  fibronectin  is  strongly
associated with hypertrophic scar formation. It is conceivable
that  a  pronounced  TGF-β  receptor  expression  and  the
presence of ED-A fibronectin enhance TGF-β-driven scarring
responses in glaucoma revision surgery.
In summary, our data are consistent with an essential role
of TGF-β in human filtering bleb scarring and suggest that
specific therapies targeting relevant cell-matrix interactions
and TGF-β signaling may be of particular benefit in our care
for patients undergoing revision glaucoma surgery.
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